RxDoctor Payments Data

John Syptak, MD

Family Medicine · Harrisonburg, VANPI 1679574321

Payments from drug & device makers

$12,255in general payments, 2019–2025

Across 819 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Pfizer$1K
  • AbbVie$988
  • Amgen$979
  • Boehringer Ingelheim$906
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$12,237100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,255 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$309,276
Medicare patients
407
Services billed
8,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$79,485
XareltoRivaroxaban29$43,759
OzempicSemaglutide29$36,309
FarxigaDapagliflozin Propanediol38$35,032
MounjaroTirzepatide20$30,265
JanuviaSitagliptin Phosphate22$25,995
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$17,204
JardianceEmpagliflozin12$14,679
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$6,811
Atorvastatin Calcium644$6,230
Ezetimibe126$3,031
Rosuvastatin Calcium197$2,379
Ezetimibe-SimvastatinEzetimibe/Simvastatin13$2,242
Omega-3 Acid Ethyl Esters67$2,040
Simvastatin179$1,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,082$79,48599 claims
Johnson & JohnsonXarelto$211$43,75929 claims
Novo NordiskOzempic$1,643$36,30929 claims
AstraZenecaFarxiga$1,920$35,03238 claims
Lilly USA, LLCMounjaro$856$30,26520 claims
MerckJanuvia$186$25,99522 claims
GSKTrelegy Ellipta$292$17,20417 claims
Boehringer IngelheimJardiance$906$14,67912 claims
Sanofi-aventis U.S. LLCLantus$45$1,53612 claims
AbbVieSynthroid$988$73620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Harrisonburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →